Table 1 |
|||||||
|
Characteristics of the patients with Kawasaki disease (KD) and healthy children (control group) |
|||||||
|
Characteristic |
Kawasaki disease |
Control |
|||||
|
Acute stage |
P |
Afebrile stage |
P |
Subacute stage |
P |
||
|
|
|||||||
|
Boys/girls, number |
22/18 |
NS |
11/4 |
||||
|
Age, months (range) |
23.2 (5.1-72.0) |
NS |
63.7 (2.6-109.0) |
||||
|
Days of fever (range) |
6.3 (3.0-15.0) |
-- |
-- |
||||
|
Resistin, 102 ng/ml |
0.38 (0.25) |
0.001 |
0.24 (0.22) ** |
0.360 |
0.14 (0.09) **▲ |
0.405 |
0.19 (0.16) |
|
S100A12, 102 ng/ml |
5.33 (3.23) |
0.001 |
4.07 (3.52) * |
0.031 |
2.62 (2.64) **▲ |
0.542 |
2.05 (1.81) |
|
sRAGE, 102 pg/ml |
3. 00 (1.91) |
0.000 |
5.75 (2.83) ** |
0.001 |
6.83 (3.07) ** |
0.018 |
9.04 (5.28) |
|
Resistin × S100A12, 104 |
2.61 (2.58) |
0.000 |
1.20 (1.19) ** |
0.122 |
0.24 (0.23) **▲ |
0.877 |
0.32 (0.26) |
|
Resistin/sRAGE, 102 |
2.13 (1.89) |
0.000 |
0.39 (0.28) ** |
0.708 |
0.21 (0.14) ** |
0.884 |
0.26 (0.21) |
|
S100A12/sRAGE, 103 |
2.61 (2.02) |
0.000 |
0.84 (0.69) ** |
0.107 |
0.30 (0.25) ** |
0.835 |
0.23 (0.19) |
|
WBCs, 104/ul |
1.39 (0.49) |
-- |
1.01 (0.51) ** |
-- |
1.01 (0.51) ** |
-- |
-- |
|
Neutrophils, % |
55.6 (18.8) |
-- |
33.2 (17.2) ** |
-- |
33.4 (17.6) ** |
-- |
-- |
|
Lymphocytes, % |
32.5 (15.1) |
-- |
50.9 (16.6) ** |
-- |
54.3 (16.7) ** |
-- |
-- |
|
Monocytes, % |
7.81 (3.98) |
-- |
11.6 (16.6) |
-- |
8.77 (2.94) |
-- |
-- |
|
Platelets, 105/ul |
4.23 (1.44) |
-- |
5.68 (2.09) ** |
-- |
6.79 (1.87) **▲▲ |
-- |
-- |
|
CRP, mg/l |
75.1 (49.1) |
-- |
25.0 (33.8) ** |
-- |
3.25 (4.12) **▲▲ |
-- |
-- |
|
ESR, mm/h |
67.7 (29.7) |
-- |
78.8 (30.4) ** |
-- |
59.2 (28.3) ▲▲ |
-- |
-- |
|
|
|||||||
|
Results are mean (SD) unless stated otherwise. All P-values are for patients versus healthy controls. NS, not significant; sRAGE, soluble receptor for advanced glycation end products; WBCs, white blood cells; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate. *P < 0.05, **P < 0.01 compared with acute stage; ▲P < 0.05, ▲▲P < 0.01 compared with afebrile stage. |
|||||||
|
Qi et al. Arthritis Research & Therapy 2012 14:R251 doi:10.1186/ar4094 |
|||||||
